Clinical Trial Update: Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating injection site tolerability, safety, and pharmacokinetics/pharmacodynamics after a single subcutaneous dose of alirocumab.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• Alirocumab (SAR236553/REGN727) (alirocumab)

Snippet

Sponsor: Sanofi | Conditions: Hypercholesterolemia | Phase 1 | Status: COMPLETED